Mesoblast Limited (MESO) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $13.93: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 14.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Rich valuation; Negative price momentum.
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as... Read more
Sell if holding. Engine safety override at $13.93: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 14.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Rich valuation; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Score 4.1/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity 76d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity and death cross (50MA < 200MA). Suitability: aggressive.
Recent developments
updated 2026-06-12Recent Developments — Mesoblast Limited
Latest news
- NEWS 10 Health Care Stocks With Whale Alerts In Today's Session — benzinga Jun 1, 2026 neutral
- NEWS Alpha Buying: Insider Conviction in High-Risk Biotech — benzinga May 7, 2026 neutral
- NEWS Reported Earlier, Mesoblast Reports $30.3M Ryoncil Net Revenues In Q3, $122M Cash On Hand And Achieved Patient Recruitme — benzinga Apr 30, 2026 positive
- NEWS Reported Earlier, Mesoblast Reaches Patient Recruitment Target In Phase 3 Trial For Non-Opioid Chronic Low Back Pain The — benzinga Apr 29, 2026 positive
- NEWS Reported Earlier, Mesoblast Acquires Exclusive Worldwide License To Mayo Clinic-Developed CAR Technology Platform To Boo — benzinga Apr 15, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $13.93: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 14.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Rich valuation; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Prior stop was $13.29. Score 4.1/10, moderate confidence.
Take-profit target: $29.75 (+113.6% upside). Prior stop was $13.29. Stop-loss: $13.29.
Quality below floor (2.3 < 4.0); Value-trap signals (2/5): Margin compression (op margin -39.5%), Material insider selling (18 sells, 0.19% of cap).
Mesoblast Limited trades at a P/E of N/A (forward -201.7). TrendMatrix value score: 0.0/10. Verdict: Sell.
10 analysts cover MESO with a consensus score of 4.1/5. Average price target: $35.
What does Mesoblast Limited do?Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in...
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.